Mitteilungsseiten des Deutschen Zentralkomitees zur Bekämpfung der Tuberkulose (DZK)

• Literatur

• 1 McQuaid CF, Vassall A, Cohen T. et al. The impact of COVID-19 on TB: a review of the data. Int J Tuberc Lung Dis 2021; 25: 819-821
• 2 Di Gennaro F, Gualano G, Timelli L. et al. Increase in Tuberculosis Diagnostic Delay during First Wave of the COVID-19 Pandemic: Data from an Italian Infectious Disease Referral Hospital. Antibiotics (Basel) 2021; 10: 272
• 3 Riou C, du Bruyn E, Stek C. et al. Relationship of SARS-CoV-2-specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection. J Clin Invest 2021; 131: e149125
• 4 Otto-Knapp R, Häcker B, Breuer C. et al. [DZK Recommendations for Tuberculosis, BCG and COVID-19 in Germany – (Official Abbreviation of Coronavirus Disease 2019 Caused by the New Coronavirus SARS-CoV-2)]. Pneumologie 2020; 74: 412-416
• 5 Lommatzsch M, Rabe KF, Taube C. et al. [Risk Assessment for Patients with Chronic Respiratory and Pulmonary Conditions in the Context of the SARS-CoV-2 Pandemic – Statement of the German Respiratory Society (DGP) with the Support of the German Association of Respiratory Physicians (BdP)]. Pneumologie 2021; 75: 19-30
• 6 Gillespie SH, Crook AM, McHugh TD. et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014; 371: 1577-1587
• 7 Imperial MZ, Nahid P, Phillips PPJ. et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med 2018; 24: 1708-1715
• 8 Naidoo A, Naidoo K, McIlleron H. et al. A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis. J Clin Pharmacol 2017; 57: 1369-1386
• 9 Svensson EM, Svensson RJ, Te Brake LHM. et al. The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. Clin Infect Dis 2018; 67: 34-41
• 10 Te Brake LHM, de Jager V, Narunsky K. et al. Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg⁻¹ rifampicin. Eur Respir J 2021; 58: 2000955
• 11 Dorman SE, Nahid P, Kurbatova EV. et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med 2021; 384: 1705-1718
• 12 RKI. Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2019. 2020